ErbB2 (HER-2) Monoclonal Antibody (9G6.10) | Invitrogen MA5-12759 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

ErbB2 (HER-2) Monoclonal Antibody (9G6.10)

catalog :

MA5-12759

quantity :

500 µL

price :

US 496.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

9G6.10

reactivity :

human, mouse

application :

western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - frozen section

citations: 59

Published Application/Species/Sample/Dilution	Reference
immunohistochemistry; human; fig 3a	Kang S, Wang Y, Reder N, Liu J. Multiplexed Molecular Imaging of Biomarker-Targeted SERS Nanoparticles on Fresh Tissue Specimens with Channel-Compressed Spectrometry. PLoS ONE. 2016;11:e0163473 pubmed publisher
flow cytometry; human; fig 5	Wang Y, Kang S, Khan A, Ruttner G, Leigh S, Murray M, et al. Quantitative molecular phenotyping with topically applied SERS nanoparticles for intraoperative guidance of breast cancer lumpectomy. Sci Rep. 2016;6:21242 pubmed publisher
western blot; human	Mahajan K, Lawrence H, Lawrence N, Mahajan N. ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1. J Biol Chem. 2014;289:28179-91 pubmed publisher
flow cytometry; human immunocytochemistry; human western blot; human	Galletti G, Sung M, Vahdat L, Shah M, Santana S, Altavilla G, et al. Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab Chip. 2014;14:147-56 pubmed publisher
ELISA; human	Jin H, Daly D, Marks J, Zangar R. Oxidatively modified proteins as plasma biomarkers in breast cancer. Cancer Biomark. 2013;13:193-200 pubmed publisher
immunocytochemistry; human; 1:200	Hernandez L, Flenker K, Hernandez F, Klingelhutz A, McNamara J, Giangrande P. Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers. Pharmaceuticals (Basel). 2013;6:295-319 pubmed
immunocytochemistry; human; 20 ug/ml western blot; human; 2 ug/ml	Gunaherath G, Marron M, Wijeratne E, Whitesell L, Gunatilaka A. Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors. Bioorg Med Chem. 2013;21:5118-29 pubmed publisher
flow cytometry; human	Mosoyan G, Nagi C, Marukian S, Teixeira A, Simonian A, Resnick Silverman L, et al. Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential. PLoS ONE. 2013;8:e55145 pubmed publisher
immunocytochemistry; human	Miller K, Koide A, Leung B, Fitzsimmons J, Yoder B, Yuan H, et al. T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment. PLoS ONE. 2012;7:e43746 pubmed publisher
immunohistochemistry; human	Hwang S, Bae J, Lee H, Kim H. Circulating Tumor Cells Detected by RT-PCR for CK-20 before Surgery Indicate Worse Prognostic Impact in Triple-Negative and HER2 Subtype Breast Cancer. J Breast Cancer. 2012;15:34-42 pubmed publisher
ELISA; human	Huang C, Chaudhery V, Pokhriyal A, George S, Polans J, Lu M, et al. Multiplexed cancer biomarker detection using quartz-based photonic crystal surfaces. Anal Chem. 2012;84:1126-33 pubmed publisher
immunohistochemistry; human	Menju T, Hashimoto S, Hashimoto A, Otsuka Y, Handa H, Ogawa E, et al. Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma. PLoS ONE. 2011;6:e25301 pubmed publisher
immunohistochemistry; human	Lee Y, Huh S, Lee D, Yoon H, Seol Y, Choi Y, et al. Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes. J Breast Cancer. 2011;14:140-6 pubmed publisher
immunocytochemistry; human; 2.5 ug/ml	Eifler R, Lind J, Falkenhagen D, Weber V, Fischer M, Zeillinger R. Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept. Cytometry B Clin Cytom. 2011;80:100-11 pubmed publisher
flow cytometry; human	Milano F, Guarriera M, Rygiel A, Krishnadath K. Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery. PLoS ONE. 2010;5:e12424 pubmed publisher
immunoprecipitation; human	Mahajan K, Challa S, Coppola D, Lawrence H, Luo Y, Gevariya H, et al. Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate. 2010;70:1274-85 pubmed publisher
immunocytochemistry; human western blot; human	Pfister A, Wood R, Salas P, Zea D, Ramsauer V. Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling. J Cell Biochem. 2010;111:643-52 pubmed publisher
immunohistochemistry; human	Kwon H, Oh S, Kim S, Lee S, Kwon K, Choi Y, et al. Clinical outcomes and breast cancer subtypes in patients with brain metastases. Onkologie. 2010;33:146-52 pubmed publisher
immunoprecipitation; human western blot; human	Mahajan K, Coppola D, Challa S, Fang B, Chen Y, Zhu W, et al. Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS ONE. 2010;5:e9646 pubmed publisher
immunoprecipitation; human	Kimple R, Vaseva A, Cox A, Baerman K, Calvo B, Tepper J, et al. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. Clin Cancer Res. 2010;16:912-23 pubmed publisher
immunohistochemistry; human; 1:100	van der Groep P, van Diest P, Menko F, Bart J, de Vries E, van der Wall E. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers. J Clin Pathol. 2009;62:926-30 pubmed publisher
immunohistochemistry; human; 1:250	Milano F, Jorritsma T, Rygiel A, Bergman J, Sondermeijer C, ten Brinke A, et al. Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment. Scand J Immunol. 2008;68:616-23 pubmed publisher
flow cytometry; human immunocytochemistry; human	Vernet E, Konrad A, Lundberg E, Nygren P, Gräslund T. Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule. J Immunol Methods. 2008;338:1-6 pubmed publisher
immunocytochemistry; human	Strohecker A, Yehiely F, Chen F, Cryns V. Caspase cleavage of HER-2 releases a Bad-like cell death effector. J Biol Chem. 2008;283:18269-82 pubmed publisher
immunocytochemistry; human; 1:10	Katsumi Y, Kuwahara Y, Tamura S, Kikuchi K, Otabe O, Tsuchiya K, et al. Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity. Clin Cancer Res. 2008;14:1192-9 pubmed publisher
immunocytochemistry; human; 1:100	Schulz T, Swistowska A, Liu Y, Swistowski A, Palmarini G, Brimble S, et al. A large-scale proteomic analysis of human embryonic stem cells. BMC Genomics. 2007;8:478 pubmed
flow cytometry; human western blot; human	Fan Y, Wong L, Ding J, Spiridonov N, Johnson R, Johnson G. Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism. J Biol Chem. 2008;283:1588-96 pubmed
immunohistochemistry; human; 1:100	Elliott D, Sherman S, Busaidy N, Williams M, Santarpia L, Clayman G, et al. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol. 2008;39:15-20 pubmed
flow cytometry; mouse	Xu Y, Darcy P, Kershaw M. Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, erbB2. Cancer Gene Ther. 2007;14:773-80 pubmed
flow cytometry; human	Garrett J, Rawale S, Allen S, Phillips G, Forni G, Morris J, et al. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. J Immunol. 2007;178:7120-31 pubmed
flow cytometry; human	Zhang J, Eguchi J, Kruse C, Gomez G, Fakhrai H, Schroter S, et al. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res. 2007;13:566-575 pubmed publisher
immunoprecipitation; human western blot; human	Muraoka Cook R, Caskey L, Sandahl M, Hunter D, Husted C, Strunk K, et al. Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1. Mol Cell Biol. 2006;26:6412-24 pubmed
flow cytometry; human; 5 ug/ml	Chan C, Metz M, Kane S. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat. 2005;91:187-201 pubmed
immunoprecipitation; human	Liu Y, Majumder S, McCall W, Sartor C, Mohler J, Gregory C, et al. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res. 2005;65:3404-9 pubmed
immunoprecipitation; human	Gregory C, Whang Y, McCall W, Fei X, Liu Y, Ponguta L, et al. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res. 2005;11:1704-12 pubmed
flow cytometry; human	Dakappagari N, Lute K, Rawale S, Steele J, Allen S, Phillips G, et al. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. J Biol Chem. 2005;280:54-63 pubmed
ELISA; human; tbl 2	Traxler P, Allegrini P, Brandt R, Brueggen J, Cozens R, Fabbro D, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004;64:4931-41 pubmed
	Wu X, Subramaniam M, Negron V, Cicek M, Reynolds C, Lingle W, et al. Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody. J Cell Biochem. 2012;113:711-23 pubmed publisher
	Dragowska W, Warburton C, Yapp D, Minchinton A, Hu Y, Waterhouse D, et al. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res. 2004;2:606-19 pubmed
	Abuharbeid S, Apel J, Sander M, Fiedler B, Langer M, Zuzarte M, et al. Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochem Biophys Res Commun. 2004;321:403-12 pubmed
	Kershaw M, Jackson J, Haynes N, Teng M, Moeller M, Hayakawa Y, et al. Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol. 2004;173:2143-50 pubmed
	Kansra S, Stoll S, Johnson J, Elder J. Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK. Mol Biol Cell. 2004;15:4299-309 pubmed
	Tanimura K, Nakago S, Murakoshi H, Takekida S, Moriyama T, Matsuo H, et al. Changes in the expression and cytological localization of betacellulin and its receptors (ErbB-1 and ErbB-4) in the trophoblasts in human placenta over the course of pregnancy. Eur J Endocrinol. 2004;151:93-101 pubmed
	Bennasroune A, Fickova M, Gardin A, Dirrig Grosch S, Aunis D, Cremel G, et al. Transmembrane peptides as inhibitors of ErbB receptor signaling. Mol Biol Cell. 2004;15:3464-74 pubmed
	Tedesco K, Thor A, Johnson D, Shyr Y, Blum K, Goldstein L, et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol. 2004;22:1071-7 pubmed
	Punj V, Graves J, Mehta R. Effect of vitamin D analog (1alpha hydroxy D5) immunoconjugated to Her-2 antibody on breast cancer. Int J Cancer. 2004;108:922-9 pubmed
	Mortensen K, Larsson L. Effects of cytochalasin D on the actin cytoskeleton: association of neoformed actin aggregates with proteins involved in signaling and endocytosis. Cell Mol Life Sci. 2003;60:1007-12 pubmed
	Ramsauer V, Carraway C, Salas P, Carraway K. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells. J Biol Chem. 2003;278:30142-7 pubmed
	Dakappagari N, Pyles J, Parihar R, Carson W, Young D, Kaumaya P. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol. 2003;170:4242-53 pubmed
	Haynes N, Trapani J, Teng M, Jackson J, Cerruti L, Jane S, et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood. 2002;100:3155-63 pubmed
	Dillon C, Creer A, Kerr K, Kümin A, Dickson C. Basolateral targeting of ERBB2 is dependent on a novel bipartite juxtamembrane sorting signal but independent of the C-terminal ERBIN-binding domain. Mol Cell Biol. 2002;22:6553-63 pubmed
	Mackeigan J, Taxman D, Hunter D, Earp H, Graves L, Ting J. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res. 2002;8:2091-9 pubmed
	Kashentseva E, Seki T, Curiel D, Dmitriev I. Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res. 2002;62:609-16 pubmed
	Piechocki M, Pilon S, Wei W. Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J Immunol Methods. 2002;259:33-42 pubmed
	Hsieh S, Malerczyk C, Aigner A, Czubayko F. ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation. Int J Cancer. 2000;86:644-51 pubmed
	Aigner A, Hsieh S, Malerczyk C, Czubayko F. Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol. Toxicology. 2000;144:221-8 pubmed
	Kunisue H, Kurebayashi J, Otsuki T, Tang C, Kurosumi M, Yamamoto S, et al. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br J Cancer. 2000;82:46-51 pubmed
	Tang C, Concepcion X, Milan M, Gong X, Montgomery E, Lippman M. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res. 1999;59:5315-22 pubmed
	Tang C, Goldstein D, Payne J, Czubayko F, Alimandi M, Wang L, et al. ErbB-4 ribozymes abolish neuregulin-induced mitogenesis. Cancer Res. 1998;58:3415-22 pubmed

product information

Product Type :

Antibody

Product Name :

ErbB2 (HER-2) Monoclonal Antibody (9G6.10)

Catalog # :

MA5-12759

Quantity :

500 µL

Price :

US 496.00

Clonality :

Monoclonal

Purity :

Protein G

Host :

Mouse

Reactivity :

Human

Applications :

Flow Cytometry: Assay-dependent, Immunocytochemistry: 1-2 µg/mL, Immunohistochemistry (Frozen): Assay-dependent, Immunoprecipitation: 2 µg/mL

Species :

Human

Clone :

9G6.10

Isotype :

IgG1

Storage :

4° C

Description :

ErbB2 (HER2) is a receptor tyrosine kinase that is overexpressed in some breast tumors. Herceptin, used in treatment of metastatic Her2-positive cancer, is monoclonal antibody targeting this kinase.

Immunogen :

RAC311 cells transfected with SV40-neu construct, expressing human neu protein

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: Assay-dependent, Immunocytochemistry: 1-2 µg/mL, Immunohistochemistry (Frozen): Assay-dependent, Immunoprecipitation: 2 µg/mL

Aliases :

avian erythroblastosis oncogene B 2; Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog); CD antigen CD340; CD340; c-erb B2/neu protein; c-erbB2; C-erbB-2; c-neu; epidermal growth factor receptor-related protein; erbb 2; ERBB2; erb-b2; Erbb-2; ErbB2 (pTyr1139); ErbB2 (pY1139); ErbB2 phospho Y1139; erb-b2 receptor tyrosine kinase 2; her 2; HER2; HER-2; HER-2/neu; herstatin; human epidermal growth factor receptor 2; Kiaa3023; metas; Metastatic lymph node gene 19 protein; mKIAA3023; MLN 19; MLN19; NEU; Neu oncogene; NEU proto-oncogene; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; NGL; p185erbB2; p185neu; phospho ErbB2; proto-oncogene c-ErbB-2; Proto-oncogene Neu; receptor tyrosine-protein kinase erbB-2; TKR1; Tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)